Chang Gung Memorial Hospital, through its focus on clinical innovation, AI-driven care, and sustainability, the hospital is redefining what it means to deliver health for all. To date, 68 innovation projects have been successfully transferred to industry, with a cumulative licensing value of NT$389 million, 16 of which have already been commercialized. Among the most notable outcomes is the improved low-concentration atropine eye drop, developed to control childhood myopia.
Under the national Healthy Taiwan vision, Chang Gung has emerged as a pioneer in applying AI to medical practice. The hospital’s Artificial Intelligence Core Laboratory and its forthcoming AI Platform are developing applications that enhance clinical decision-making, reduce administrative workload, and advance simulation-based education. Seventeen AI models have already been deployed across Chang Gung’s network, five of which are approved by the Taiwan Food and Drug Administration. Among them is an AI-powered wrist fracture detection system with nearly 90% sensitivity, an atrial fibrillation detection model reaching 99.7% sensitivity.
【MORE】